Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
Study Details
Study Description
Brief Summary
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD. Generating such data will provide data on the use of SPD489 in the preschool ADHD population.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Single Arm There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects. |
Drug: SPD489
All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level [From start of study treatment up to safety follow-up (Week 9)]
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment-emergent if it had a start date on or after, or had a start date before but increased in severity after the first dose of investigational product.
- Change in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire at Week 8 / End of Treatment (ET) [Baseline, Week 8/ET]
Children's Sleep Habits Questionnaire is a tool designed to screen the most common sleep problems in children, and consists of 33 items for scoring. The instrument evaluates the child's sleep based on behavior within 8 different subscales: bedtime resistance, sleep-onset delay, sleep duration, sleep anxiety, night walkings, parasomnias, sleep-disordered breathing, and daytime sleepiness. Each item receives a score from 1 (problem occurs rarely) to 3 (problem usually occurs); therefore, a higher score is the worse outcome. Scale ranges are as follows: bedtime resistance: 6 to 18, sleep onset delay: 1 to 3, sleep duration: 3 to 9, sleep anxiety: 4 to 12, night walkings: 3 to 9, parasomnias: 7 to 21, sleep-disordered breathing: 3 to 9, daytime sleepiness: 8 to 24, and total disturbance (items from all scales): 33 to 99.
- Number of Participants With Suicide Related Behavior Assessed by Columbia-Suicide Severity Rating Scale Questionnaire (C-SSRS) [Baseline, Week 8/ET]
The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.
Secondary Outcome Measures
- Change From Baseline in Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Preschool Version Total Score at FoTA (Final on Treatment Assessment) [Baseline, FoTA]
The ADHD-RS-IV Preschool Version is an 18-item questionnaire that requires the respondent to rate the frequency of occurrence of ADHD symptoms as defined by Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV-TR) criteria. Each item is scored on a 4-point scale ranging from 0 (never or rarely) to 3 (very often) with total scores ranging from 0-54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17). Data presented here was analysed at Final on-Treatment Assessment (FoTA).
- Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) [FoTA]
CGI-I was performed to rate the severity of a participant's condition on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse). Data presented here was analysed at Final on-Treatment Assessment (FoTA). Improved is defined as a score of "very much improved" or "much improved".
- Area Under the Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC 0-last) of SPD489 in Plasma [Visit 7 [Dose Maintenance Phase] at pre-dose, and 1, 2, 3, 4, 6, and 8 h post-dose]
AUC 0-last is the area under the concentration-time curve from time zero to the time of the last quantifiable concentration of SPD489 in plasma. Pharmacokinetic (PK) parameters were compared against the study NRP104-201 (NCT00557011) to observe and compare the effects of SPD489.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject is a male or female aged 4-5 years inclusive at the time of consent. Only recruiting male subjects as of December 2015
-
Subject's parent or LAR must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject in accordance with the ICH GCP Guideline E6 (1996) and applicable regulations, before completing any study-related procedures.
-
Subject and parent/LAR are willing and able to comply with all of the testing and requirements defined in the protocol, including oversight of morning dosing. Specifically, the same parent/LAR should be available daily to dispense the dose of investigational product for the study duration.
-
Subject must meet DSM-IV-TR criteria for a primary diagnosis of ADHD (all subtypes) based on a detailed psychiatric evaluation conducted by a sponsor-approved clinician
-
Subject has an ADHD-RS-IV Preschool Version total score ≥93rd percentile at the Baseline Visit (Visit 0). For boys, this is a score of ≥32. For girls, this is a score of ≥24.
-
Subject has a CGI-S score ≥4 at the Baseline Visit (Visit 0).
-
Subject has a Peabody Picture Vocabulary Test, Fourth Edition standard score of ≥70 at the Screening Visit (Visit -1).
-
Subject has undergone an adequate course of non-pharmacological treatment based on investigator judgment or the subject has a severe enough condition to consider enrollment without undergoing prior non-pharmacological treatment based on investigator judgment.
-
Subject has, in the opinion of the investigator, participated in a structured group activity (e.g., preschool, sports, Sunday school) so as to assess symptoms and impairment in a setting outside the home.
-
Subject has lived with the same parent/LAR for ≥6 months.
Exclusion Criteria:
-
Subject is required to or anticipates the need to take medications that have CNS effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are taking monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
-
Subject has taken another investigational product or has taken part in a clinical study within 30 days prior to the Screening Visit (Visit -1).
-
Subject is well controlled on his/her current ADHD medication with acceptable tolerability.
-
Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that, in the investigator's opinion, would prohibit the subject from completing the study or would not be in the best interest of the subject. The additional conditions would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.
-
Subject has failed to fully respond, based on investigator judgment, to a previously administered adequate course of amphetamine therapy.
-
Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
-
Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
-
Subject has a blood pressure measurement ≥95th percentile for age, sex, and height at the Screening Visit (Visit -1) or the Baseline Visit (Visit 0).
-
Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems placing them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
-
Subject has any clinically significant electrocardiogram at the Screening Visit (Visit -1) or the Baseline Visit (Visit 0) or clinically significant laboratory abnormalities at the Screening Visit (Visit -1) based on investigator judgment.
-
Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone and thyroxine at the Screening Visit (Visit -1). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
-
Subject has a current diagnosis of adjustment disorder, autism, psychosis, or bipolar disorder.
-
Subject is currently considered at risk for suicide in the opinion of the investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded, based on the assessment of the investigator.
-
Subject has a height ≤5th percentile for age and sex at the Screening Visit (Visit -1).
-
Subject has a weight ≤5th percentile for age and sex at the Screening Visit (Visit -1).
-
Subject has a history of seizures (other than infantile febrile seizures) or a current diagnosis of Tourette's disorder.
-
Subject has a chronic or current tic disorder that is judged by the investigator to be exclusionary.
-
Subject is taking any medication that is excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | AVIDA | Newport Beach | California | United States | 92660 |
| 2 | Kennedy Krieger Institute | Baltimore | Maryland | United States | 21205 |
| 3 | Center For Psychiatry and Behavioral Medicine In | Las Vegas | Nevada | United States | 89128 |
| 4 | Duke Child and Family Center | Durham | North Carolina | United States | 27710 |
| 5 | University of Cincinnati | Cincinnati | Ohio | United States | 45219 |
| 6 | Houston Clinical Trials, LLC | Houston | Texas | United States | 77098 |
Sponsors and Collaborators
- Shire
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SPD489-211
Study Results
Participant Flow
| Recruitment Details | The study was conducted at seven sites in the United States between 15 Apr 2015 (first participant first visit) and 30 Jun 2016 (last participant last visit). |
|---|---|
| Pre-assignment Detail | A total of 24 participants were enrolled and received at least one dose. Overall 19 participants completed the study. |
| Arm/Group Title | SPD489 |
|---|---|
| Arm/Group Description | Participants received 5 milligram (mg) capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. |
| Period Title: Overall Study | |
| STARTED | 24 |
| COMPLETED | 19 |
| NOT COMPLETED | 5 |
Baseline Characteristics
| Arm/Group Title | SPD489 |
|---|---|
| Arm/Group Description | Participants received 5 milligram (mg) capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. |
| Overall Participants | 24 |
| Age (years) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [years] |
4.7
(0.48)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
6
25%
|
| Male |
18
75%
|
Outcome Measures
| Title | Number of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level |
|---|---|
| Description | An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment-emergent if it had a start date on or after, or had a start date before but increased in severity after the first dose of investigational product. |
| Time Frame | From start of study treatment up to safety follow-up (Week 9) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety analysis set consisted of all participants who had taken at least 1 dose of investigational product. Reporting groups are defined by the dose taken prior to the onset of the TEAE (Treatment Emergent Adverse Event). Number of participants analysed (N) are specific to the reporting group at the specific dose level. |
| Arm/Group Title | SPD489 5 mg | SPD489 10 mg | SPD489 15 mg | SPD489 20 mg | SPD489 30 mg | SPD489 |
|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 5 mg capsule of SPD489 orally once daily from Week 1 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 10 mg capsule of SPD489 orally once daily from Week 2 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 15 mg capsule of SPD489 orally once daily from Week 3 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 20 mg capsule of SPD489 orally once daily from Week 4 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 30 mg capsule of SPD489 orally once daily from Week 5 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 5 mg capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. |
| Measure Participants | 24 | 23 | 18 | 12 | 10 | 24 |
| Count of Participants [Participants] |
10
41.7%
|
11
NaN
|
7
NaN
|
6
NaN
|
6
NaN
|
19
NaN
|
| Title | Change in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire at Week 8 / End of Treatment (ET) |
|---|---|
| Description | Children's Sleep Habits Questionnaire is a tool designed to screen the most common sleep problems in children, and consists of 33 items for scoring. The instrument evaluates the child's sleep based on behavior within 8 different subscales: bedtime resistance, sleep-onset delay, sleep duration, sleep anxiety, night walkings, parasomnias, sleep-disordered breathing, and daytime sleepiness. Each item receives a score from 1 (problem occurs rarely) to 3 (problem usually occurs); therefore, a higher score is the worse outcome. Scale ranges are as follows: bedtime resistance: 6 to 18, sleep onset delay: 1 to 3, sleep duration: 3 to 9, sleep anxiety: 4 to 12, night walkings: 3 to 9, parasomnias: 7 to 21, sleep-disordered breathing: 3 to 9, daytime sleepiness: 8 to 24, and total disturbance (items from all scales): 33 to 99. |
| Time Frame | Baseline, Week 8/ET |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety analysis set consisted of all participants who had taken at least 1 dose of investigational product. Here number of participant analysed for the each sub-scale is specified for this endpoint. |
| Arm/Group Title | SPD489 |
|---|---|
| Arm/Group Description | Participants received 5 milligram (mg) capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. |
| Measure Participants | 24 |
| Baseline : Bedtime resistance |
9.9
(3.58)
|
| Week 8/ End of Treatment (ET) : Bedtime resistance |
9.5
(3.26)
|
| Baseline : Sleep-onset delay |
1.9
(0.85)
|
| Week 8/ ET : Sleep-onset delay |
1.8
(0.92)
|
| Baseline : Sleep duration |
4.5
(1.56)
|
| Week 8/ET : Sleep duration |
4.0
(1.27)
|
| Baseline : Sleep anxiety |
6.6
(2.52)
|
| Week 8/ET : Sleep anxiety |
5.5
(1.79)
|
| Baseline : Night walkings |
5.0
(2.10)
|
| Week 8/ET : Night wakings |
4.7
(2.00)
|
| Baseline : Parasomnias |
9.7
(2.03)
|
| Week 8/ET : Parasomnias |
8.5
(1.57)
|
| Baseline : Sleep-disordered breathing |
3.3
(0.82)
|
| Week 8/ET : Sleep-disordered breathing |
3.2
(0.66)
|
| Baseline : Daytime sleepiness |
12.1
(3.43)
|
| Week 8/ET : Daytime sleepiness |
10.0
(3.51)
|
| Title | Number of Participants With Suicide Related Behavior Assessed by Columbia-Suicide Severity Rating Scale Questionnaire (C-SSRS) |
|---|---|
| Description | The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide. |
| Time Frame | Baseline, Week 8/ET |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety analysis set consisted of all participants who had taken at least 1 dose of investigational product. |
| Arm/Group Title | SPD489 |
|---|---|
| Arm/Group Description | Participants received 5 milligram (mg) capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. |
| Measure Participants | 24 |
| Count of Participants [Participants] |
1
4.2%
|
| Title | Change From Baseline in Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Preschool Version Total Score at FoTA (Final on Treatment Assessment) |
|---|---|
| Description | The ADHD-RS-IV Preschool Version is an 18-item questionnaire that requires the respondent to rate the frequency of occurrence of ADHD symptoms as defined by Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV-TR) criteria. Each item is scored on a 4-point scale ranging from 0 (never or rarely) to 3 (very often) with total scores ranging from 0-54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17). Data presented here was analysed at Final on-Treatment Assessment (FoTA). |
| Time Frame | Baseline, FoTA |
Outcome Measure Data
| Analysis Population Description |
|---|
| Full analysis set consisted of all participants in the safety analysis set who had at least 1 post-dose ADHD-RS-IV Preschool Version total score assessment. |
| Arm/Group Title | SPD489 |
|---|---|
| Arm/Group Description | Participants received 5 milligram (mg) capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. |
| Measure Participants | 24 |
| Baseline |
43.6
(5.54)
|
| FoTA |
-26.1
(14.37)
|
| Title | Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) |
|---|---|
| Description | CGI-I was performed to rate the severity of a participant's condition on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse). Data presented here was analysed at Final on-Treatment Assessment (FoTA). Improved is defined as a score of "very much improved" or "much improved". |
| Time Frame | FoTA |
Outcome Measure Data
| Analysis Population Description |
|---|
| Full analysis set consisted of all participants in the safety analysis set who had at least 1 post-dose ADHD-RS-IV Preschool Version total score assessment. |
| Arm/Group Title | SPD489 |
|---|---|
| Arm/Group Description | Participants received 5 milligram (mg) capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. |
| Measure Participants | 24 |
| Count of Participants [Participants] |
20
83.3%
|
| Title | Area Under the Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC 0-last) of SPD489 in Plasma |
|---|---|
| Description | AUC 0-last is the area under the concentration-time curve from time zero to the time of the last quantifiable concentration of SPD489 in plasma. Pharmacokinetic (PK) parameters were compared against the study NRP104-201 (NCT00557011) to observe and compare the effects of SPD489. |
| Time Frame | Visit 7 [Dose Maintenance Phase] at pre-dose, and 1, 2, 3, 4, 6, and 8 h post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| The PK set consisted all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable. PK assessments were performed only during the Dose Maintenance Period (2 weeks) for SPD 489 10, 15 and 30 mg reporting groups. |
| Arm/Group Title | SPD489 10 mg | SPD489 15 mg | SPD489 30 mg |
|---|---|---|---|
| Arm/Group Description | Participants received 10 mg capsule of SPD489 orally once daily from Week 2 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 15 mg capsule of SPD489 orally once daily from Week 3 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 30 mg capsule of SPD489 orally once daily from Week 5 up to Week 8 based on the investigator's assessment of participants' response and tolerability. |
| Measure Participants | 1 | 2 | 5 |
| Mean (Standard Deviation) [hour*nanogram/millilitre(h*ng/mL)] |
9.8
(NA)
|
15.7
(4.1)
|
59.5
(22.0)
|
Adverse Events
| Time Frame | From Start of Treatment up to Safety Follow up (Week 9) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||||||
| Arm/Group Title | SPD489 5mg | SPD489 10mg | SPD489 15mg | SPD489 20mg | SPD489 30mg | SPD489 | ||||||
| Arm/Group Description | Participants received 5 mg capsule of SPD489 orally once daily from Week 1 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 10 mg capsule of SPD489 orally once daily from Week 2 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 15 mg capsule of SPD489 orally once daily from Week 3 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 20 mg capsule of SPD489 orally once daily from Week 4 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 30 mg capsule of SPD489 orally once daily from Week 5 up to Week 8 based on the investigator's assessment of participants' response and tolerability. | Participants received 5 mg capsule of SPD489 orally once daily and titrated up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 8 weeks. | ||||||
All Cause Mortality |
||||||||||||
| SPD489 5mg | SPD489 10mg | SPD489 15mg | SPD489 20mg | SPD489 30mg | SPD489 | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/24 (0%) | 0/23 (0%) | 0/18 (0%) | 0/12 (0%) | 0/10 (0%) | 0/24 (0%) | ||||||
Serious Adverse Events |
||||||||||||
| SPD489 5mg | SPD489 10mg | SPD489 15mg | SPD489 20mg | SPD489 30mg | SPD489 | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/24 (0%) | 0/23 (0%) | 0/18 (0%) | 0/12 (0%) | 0/10 (0%) | 0/24 (0%) | ||||||
Other (Not Including Serious) Adverse Events |
||||||||||||
| SPD489 5mg | SPD489 10mg | SPD489 15mg | SPD489 20mg | SPD489 30mg | SPD489 | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 6/24 (25%) | 7/23 (30.4%) | 7/18 (38.9%) | 6/12 (50%) | 6/10 (60%) | 15/24 (62.5%) | ||||||
| Gastrointestinal disorders | ||||||||||||
| Abdominal pain upper | 1/24 (4.2%) | 1 | 1/23 (4.3%) | 1 | 0/18 (0%) | 0 | 1/12 (8.3%) | 1 | 0/10 (0%) | 0 | 3/24 (12.5%) | 3 |
| Vomiting | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 0/12 (0%) | 0 | 1/10 (10%) | 1 | 1/24 (4.2%) | 1 |
| General disorders | ||||||||||||
| Chest discomfort | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 1/18 (5.6%) | 1 | 0/12 (0%) | 0 | 0/10 (0%) | 0 | 1/24 (4.2%) | 1 |
| Infections and infestations | ||||||||||||
| Gastroenteritis | 2/24 (8.3%) | 2 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 0/12 (0%) | 0 | 0/10 (0%) | 0 | 2/24 (8.3%) | 2 |
| Gastroenteritis viral | 0/24 (0%) | 0 | 1/23 (4.3%) | 1 | 0/18 (0%) | 0 | 0/12 (0%) | 0 | 1/10 (10%) | 1 | 2/24 (8.3%) | 2 |
| Upper respiratory tract infection | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 3/18 (16.7%) | 3 | 1/12 (8.3%) | 1 | 0/10 (0%) | 0 | 4/24 (16.7%) | 4 |
| Investigations | ||||||||||||
| Blood pressure diastolic increased | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 1/12 (8.3%) | 1 | 0/10 (0%) | 0 | 1/24 (4.2%) | 1 |
| Weight decreased | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 2/18 (11.1%) | 2 | 0/12 (0%) | 0 | 0/10 (0%) | 0 | 2/24 (8.3%) | 2 |
| Metabolism and nutrition disorders | ||||||||||||
| Decreased appetite | 1/24 (4.2%) | 1 | 1/23 (4.3%) | 1 | 1/18 (5.6%) | 1 | 3/12 (25%) | 3 | 2/10 (20%) | 2 | 8/24 (33.3%) | 8 |
| Psychiatric disorders | ||||||||||||
| Affect lability | 0/24 (0%) | 0 | 1/23 (4.3%) | 1 | 1/18 (5.6%) | 1 | 1/12 (8.3%) | 1 | 0/10 (0%) | 0 | 3/24 (12.5%) | 3 |
| Anxiety | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 0/12 (0%) | 0 | 1/10 (10%) | 1 | 1/24 (4.2%) | 1 |
| Initial insomnia | 1/24 (4.2%) | 1 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 1/12 (8.3%) | 1 | 0/10 (0%) | 0 | 2/24 (8.3%) | 2 |
| Insomnia | 1/24 (4.2%) | 1 | 2/23 (8.7%) | 2 | 0/18 (0%) | 0 | 1/12 (8.3%) | 1 | 2/10 (20%) | 2 | 4/24 (16.7%) | 6 |
| Irritability | 1/24 (4.2%) | 1 | 2/23 (8.7%) | 2 | 0/18 (0%) | 0 | 0/12 (0%) | 0 | 0/10 (0%) | 0 | 3/24 (12.5%) | 3 |
| Middle insomnia | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 1/12 (8.3%) | 1 | 0/10 (0%) | 0 | 1/24 (4.2%) | 1 |
| Mood swings | 0/24 (0%) | 0 | 1/23 (4.3%) | 1 | 0/18 (0%) | 0 | 1/12 (8.3%) | 1 | 0/10 (0%) | 0 | 1/24 (4.2%) | 2 |
| Respiratory, thoracic and mediastinal disorders | ||||||||||||
| Nasal congestion | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 0/12 (0%) | 0 | 1/10 (10%) | 1 | 1/24 (4.2%) | 1 |
| Skin and subcutaneous tissue disorders | ||||||||||||
| Urticaria | 0/24 (0%) | 0 | 0/23 (0%) | 0 | 0/18 (0%) | 0 | 0/12 (0%) | 0 | 1/10 (10%) | 1 | 1/24 (4.2%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.
Results Point of Contact
| Name/Title | Study Director |
|---|---|
| Organization | Shire |
| Phone | +1 866 842 5335 |
| ClinicalTransparency@shire.com |
- SPD489-211